Skip to main content
Top
Published in: Endocrine 2/2022

08-06-2022 | Glucocorticoid | Original Article

Clinical, biochemical, and miRNA profile of subjects with positive screening of primary aldosteronism and nonclassic apparent mineralocorticoid excess

Authors: Alejandra Tapia-Castillo, Cristian A. Carvajal, Jorge A. Pérez, Carlos E. Fardella

Published in: Endocrine | Issue 2/2022

Login to get access

Abstract

Primary aldosteronism (PA) and nonclassic apparent mineralocorticoid excess (NCAME) have been recognized as endocrine-related conditions having a broad clinical-biochemical spectrum, spanning from normotension to severe arterial hypertension (AHT). However, the coexistence of both phenotypes have not been reported to date.

Aim

To identify and characterize clinical and biochemical parameters of subjects with both PA and NCAME conditions (NCAME&PA) and study the miRNA cargo in their urinary extracellular vesicles as potential biomarkers for this novel condition.

Methods

We performed a cross-sectional study of 206 Chilean adult subjects from a primary care cohort. We measured blood pressure (BP), cortisol (F), cortisone (E), aldosterone, plasma renin activity (PRA), microalbuminuria (MAC), plasma NGAL, MMP9, fractional-potassium-excretion (FEK). Subjects were classified as NCAME&PA, PA, NCAME, essential hypertensives (EH), or healthy controls (CTL). EV-miRNAs were quantified by Taqman-qPCR.

Results

We found that 30.6% subjects had an abnormal endocrine phenotype: NCAME&PA (6.8%), PA (11.2%) or NCAME (12.6%), and the prevalence of AHT was 92.9%, 82.6%, and 65%, respectively. NCAME&PA subjects had both lower cortisone (p < 0.05) and lower PRA (p < 0.0001), higher FEK (p = 0.02) and higher MAC (p = 0.01) than EH or CTL. NCAME&PA subjects had also higher NGAL levels than CTL and PA (p < 0.05). Exosome miR-192, miR-133a and miR-21 expression decreased with phenotype severity and correlated with BP and PRA (p < 0.05).

Conclusion

We identified adult subjects with a combined condition of NCAME and PA associated with higher BP, increased renal and endothelial damage markers than control and EH. Additionally, we observed a differential expression of a specific miRNAs, suggesting a potential role of these miRNAs associated to this novel combined phenotype.
Appendix
Available only for authorised users
Literature
1.
go back to reference J.W. Funder, Apparent mineralocorticoid excess. J. Steroid Biochem Mol. Biol. 165(Pt A), 151–153 (2017)PubMedCrossRef J.W. Funder, Apparent mineralocorticoid excess. J. Steroid Biochem Mol. Biol. 165(Pt A), 151–153 (2017)PubMedCrossRef
2.
go back to reference K. Kosicka, M. Cymerys, A. Majchrzak-Celinska, M. Chuchracki, F.K. Glowka, 11beta-Hydroxysteroid dehydrogenase type 2 in hypertension: comparison of phenotype and genotype analysis. J. Hum. Hypertens. 27(8), 510–515 (2013)PubMedCrossRef K. Kosicka, M. Cymerys, A. Majchrzak-Celinska, M. Chuchracki, F.K. Glowka, 11beta-Hydroxysteroid dehydrogenase type 2 in hypertension: comparison of phenotype and genotype analysis. J. Hum. Hypertens. 27(8), 510–515 (2013)PubMedCrossRef
3.
go back to reference J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata, M. Stowasser, W.F. Young Jr., The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101(5), 1889–1916 (2016)PubMedCrossRef J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata, M. Stowasser, W.F. Young Jr., The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101(5), 1889–1916 (2016)PubMedCrossRef
4.
go back to reference C.A. Carvajal, A. Tapia-Castillo, A. Vecchiola, R. Baudrand, C.E. Fardella, Classic and nonclassic apparent mineralocorticoid excess syndrome. J. Clin. Endocrinol. Metab. 105, 4 (2020)CrossRef C.A. Carvajal, A. Tapia-Castillo, A. Vecchiola, R. Baudrand, C.E. Fardella, Classic and nonclassic apparent mineralocorticoid excess syndrome. J. Clin. Endocrinol. Metab. 105, 4 (2020)CrossRef
5.
go back to reference A. Vaidya, P. Mulatero, R. Baudrand, G.K. Adler, The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr. Rev. 39(6), 1057–1088 (2018)PubMedPubMedCentralCrossRef A. Vaidya, P. Mulatero, R. Baudrand, G.K. Adler, The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr. Rev. 39(6), 1057–1088 (2018)PubMedPubMedCentralCrossRef
6.
go back to reference P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, J.J. Mourad, Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45(8), 1243–1248 (2005)PubMedCrossRef P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, J.J. Mourad, Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45(8), 1243–1248 (2005)PubMedCrossRef
7.
go back to reference A.A. Herrada, F.J. Contreras, N.P. Marini, C.A. Amador, P.A. Gonzalez, C.M. Cortes, C.A. Riedel, C.A. Carvajal, F. Figueroa, L.F. Michea, C.E. Fardella, A.M. Kalergis, Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J. Immunol. 184(1), 191–202 (2010)PubMedCrossRef A.A. Herrada, F.J. Contreras, N.P. Marini, C.A. Amador, P.A. Gonzalez, C.M. Cortes, C.A. Riedel, C.A. Carvajal, F. Figueroa, L.F. Michea, C.E. Fardella, A.M. Kalergis, Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J. Immunol. 184(1), 191–202 (2010)PubMedCrossRef
8.
go back to reference C.A. Carvajal, A.A. Herrada, C.R. Castillo, F.J. Contreras, C.B. Stehr, L.M. Mosso, A.M. Kalergis, C.E. Fardella, Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha. J. Endocrinol. Investig. 32(9), 759–765 (2009)CrossRef C.A. Carvajal, A.A. Herrada, C.R. Castillo, F.J. Contreras, C.B. Stehr, L.M. Mosso, A.M. Kalergis, C.E. Fardella, Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha. J. Endocrinol. Investig. 32(9), 759–765 (2009)CrossRef
9.
go back to reference V. Leroy, S. De Seigneux, V. Agassiz, U. Hasler, M.E. Rafestin-Oblin, M. Vinciguerra, P.Y. Martin, E. Feraille, Aldosterone activates NF-kappaB in the collecting duct. J. Am. Soc. Nephrol. 20(1), 131–144 (2009)PubMedPubMedCentralCrossRef V. Leroy, S. De Seigneux, V. Agassiz, U. Hasler, M.E. Rafestin-Oblin, M. Vinciguerra, P.Y. Martin, E. Feraille, Aldosterone activates NF-kappaB in the collecting duct. J. Am. Soc. Nephrol. 20(1), 131–144 (2009)PubMedPubMedCentralCrossRef
10.
go back to reference C.A. Carvajal, A. Tapia-Castillo, C.P. Valdivia, F. Allende, S. Solari, C.F. Lagos, C. Campino, A. Martinez-Aguayo, A. Vecchiola, C. Pinochet, C. Godoy, V. Iturrieta, R. Baudrand, C.E. Fardella, Serum cortisol and cortisone as potential biomarkers of partial 11beta-hydroxysteroid dehydrogenase type 2 deficiency. Am. J. Hypertens. 31(8), 910–918 (2018)PubMedCrossRef C.A. Carvajal, A. Tapia-Castillo, C.P. Valdivia, F. Allende, S. Solari, C.F. Lagos, C. Campino, A. Martinez-Aguayo, A. Vecchiola, C. Pinochet, C. Godoy, V. Iturrieta, R. Baudrand, C.E. Fardella, Serum cortisol and cortisone as potential biomarkers of partial 11beta-hydroxysteroid dehydrogenase type 2 deficiency. Am. J. Hypertens. 31(8), 910–918 (2018)PubMedCrossRef
11.
go back to reference A. Tapia-Castillo, R. Baudrand, A. Vaidya, C. Campino, F. Allende, C. Valdivia, A. Vecchiola, C.F. Lagos, C.A. Fuentes, S. Solari, A. Martinez-Aguayo, H. Garcia, C.A. Carvajal, C.E. Fardella, Clinical, biochemical, and genetic characteristics of “nonclassic” apparent mineralocorticoid excess syndrome. J. Clin. Endocrinol. Metab. 104(2), 595–603 (2019)PubMedCrossRef A. Tapia-Castillo, R. Baudrand, A. Vaidya, C. Campino, F. Allende, C. Valdivia, A. Vecchiola, C.F. Lagos, C.A. Fuentes, S. Solari, A. Martinez-Aguayo, H. Garcia, C.A. Carvajal, C.E. Fardella, Clinical, biochemical, and genetic characteristics of “nonclassic” apparent mineralocorticoid excess syndrome. J. Clin. Endocrinol. Metab. 104(2), 595–603 (2019)PubMedCrossRef
12.
go back to reference K.C. Gilbert, N.J. Brown, Aldosterone and inflammation. Curr. Opin. Endocrinol., diabetes, Obes. 17(3), 199–204 (2010)CrossRef K.C. Gilbert, N.J. Brown, Aldosterone and inflammation. Curr. Opin. Endocrinol., diabetes, Obes. 17(3), 199–204 (2010)CrossRef
13.
go back to reference J.M. Connell, S.M. MacKenzie, E.M. Freel, R. Fraser, E. Davies, A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr. Rev. 29(2), 133–154 (2008)PubMedCrossRef J.M. Connell, S.M. MacKenzie, E.M. Freel, R. Fraser, E. Davies, A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr. Rev. 29(2), 133–154 (2008)PubMedCrossRef
14.
go back to reference G.P. Rossi, G. Bernini, G. Desideri, B. Fabris, C. Ferri, G. Giacchetti, C. Letizia, M. Maccario, M. Mannelli, M.J. Matterello, D. Montemurro, G. Palumbo, D. Rizzoni, E. Rossi, A.C. Pessina, F. Mantero, P.S. Participants, Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 48(2), 232–238 (2006)PubMedCrossRef G.P. Rossi, G. Bernini, G. Desideri, B. Fabris, C. Ferri, G. Giacchetti, C. Letizia, M. Maccario, M. Mannelli, M.J. Matterello, D. Montemurro, G. Palumbo, D. Rizzoni, E. Rossi, A.C. Pessina, F. Mantero, P.S. Participants, Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 48(2), 232–238 (2006)PubMedCrossRef
15.
go back to reference S. Friso, C.A. Carvajal, C.E. Fardella, O. Olivieri, Epigenetics and arterial hypertension: the challenge of emerging evidence. Transl. Res. 165(1), 154–165 (2015)PubMedCrossRef S. Friso, C.A. Carvajal, C.E. Fardella, O. Olivieri, Epigenetics and arterial hypertension: the challenge of emerging evidence. Transl. Res. 165(1), 154–165 (2015)PubMedCrossRef
16.
go back to reference Y. Sun, S. Koo, N. White, E. Peralta, C. Esau, N.M. Dean, R.J. Perera, Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res 32(22), e188 (2004)PubMedPubMedCentralCrossRef Y. Sun, S. Koo, N. White, E. Peralta, C. Esau, N.M. Dean, R.J. Perera, Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res 32(22), e188 (2004)PubMedPubMedCentralCrossRef
17.
go back to reference Z. Tian, A.S. Greene, J.L. Pietrusz, I.R. Matus, M. Liang, MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 18(3), 404–411 (2008)PubMedPubMedCentralCrossRef Z. Tian, A.S. Greene, J.L. Pietrusz, I.R. Matus, M. Liang, MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res. 18(3), 404–411 (2008)PubMedPubMedCentralCrossRef
18.
go back to reference L. Shi, J. Liao, B. Liu, F. Zeng, L. Zhang, Mechanisms and therapeutic potential of microRNAs in hypertension. Drug Discov. Today 20(10), 1188–1204 (2015)PubMedPubMedCentralCrossRef L. Shi, J. Liao, B. Liu, F. Zeng, L. Zhang, Mechanisms and therapeutic potential of microRNAs in hypertension. Drug Discov. Today 20(10), 1188–1204 (2015)PubMedPubMedCentralCrossRef
19.
go back to reference S. Batkai, T. Thum, MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr. Hypertens. Rep. 14(1), 79–87 (2012)PubMedCrossRef S. Batkai, T. Thum, MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr. Hypertens. Rep. 14(1), 79–87 (2012)PubMedCrossRef
20.
go back to reference Y. Cheng, Q. Zeng, Q. Han, W. Xia, Effect of pH, temperature and freezing-thawing on quantity changes and cellular uptake of exosomes. Protein Cell 10(4), 295–299 (2019)PubMedCrossRef Y. Cheng, Q. Zeng, Q. Han, W. Xia, Effect of pH, temperature and freezing-thawing on quantity changes and cellular uptake of exosomes. Protein Cell 10(4), 295–299 (2019)PubMedCrossRef
21.
go back to reference C. Chen, C. Lu, Y. Qian, H. Li, Y. Tan, L. Cai, H. Weng, Urinary miR-21 as a potential biomarker of hypertensive kidney injury and fibrosis. Sci. Rep. 7(1), 17737 (2017)PubMedPubMedCentralCrossRef C. Chen, C. Lu, Y. Qian, H. Li, Y. Tan, L. Cai, H. Weng, Urinary miR-21 as a potential biomarker of hypertensive kidney injury and fibrosis. Sci. Rep. 7(1), 17737 (2017)PubMedPubMedCentralCrossRef
22.
go back to reference A. Decmann, G. Nyiro, O. Darvasi, P. Turai, I. Bancos, R.J. Kaur, R. Pezzani, M. Iacobone, I. Kraljevic, D. Kastelan, M. Parasiliti-Caprino, M. Maccario, N. Nirschl, D. Heinrich, M. Reincke, A. Patocs, P. Igaz, Circulating miRNA expression profiling in primary aldosteronism. Front Endocrinol. 10, 739 (2019)CrossRef A. Decmann, G. Nyiro, O. Darvasi, P. Turai, I. Bancos, R.J. Kaur, R. Pezzani, M. Iacobone, I. Kraljevic, D. Kastelan, M. Parasiliti-Caprino, M. Maccario, N. Nirschl, D. Heinrich, M. Reincke, A. Patocs, P. Igaz, Circulating miRNA expression profiling in primary aldosteronism. Front Endocrinol. 10, 739 (2019)CrossRef
23.
go back to reference E. Mensà, M. Guescini, A. Giuliani, M.G. Bacalini, D. Ramini, G. Corleone, M. Ferracin, G. Fulgenzi, L. Graciotti, F. Prattichizzo, L. Sorci, M. Battistelli, V. Monsurrò, A.R. Bonfigli, M. Cardelli, R. Recchioni, F. Marcheselli, S. Latini, S. Maggio, M. Fanelli, S. Amatori, G. Storci, A. Ceriello, V. Stocchi, M. De Luca, L. Magnani, M.R. Rippo, A.D. Procopio, C. Sala, I. Budimir, C. Bassi, M. Negrini, P. Garagnani, C. Franceschi, J. Sabbatinelli, M. Bonafè, F. Olivieri, Small extracellular vesicles deliver miR-21 and miR-217 as pro-senescence effectors to endothelial cells. J. Extracell. Vesicles 9(1), 1725285 (2020)PubMedPubMedCentralCrossRef E. Mensà, M. Guescini, A. Giuliani, M.G. Bacalini, D. Ramini, G. Corleone, M. Ferracin, G. Fulgenzi, L. Graciotti, F. Prattichizzo, L. Sorci, M. Battistelli, V. Monsurrò, A.R. Bonfigli, M. Cardelli, R. Recchioni, F. Marcheselli, S. Latini, S. Maggio, M. Fanelli, S. Amatori, G. Storci, A. Ceriello, V. Stocchi, M. De Luca, L. Magnani, M.R. Rippo, A.D. Procopio, C. Sala, I. Budimir, C. Bassi, M. Negrini, P. Garagnani, C. Franceschi, J. Sabbatinelli, M. Bonafè, F. Olivieri, Small extracellular vesicles deliver miR-21 and miR-217 as pro-senescence effectors to endothelial cells. J. Extracell. Vesicles 9(1), 1725285 (2020)PubMedPubMedCentralCrossRef
24.
go back to reference Z.Z. Liu, P.A. Jose, J. Yang, C. Zeng, Importance of extracellular vesicles in hypertension. Exp. Biol. Med. 246(3), 342–353 (2020)CrossRef Z.Z. Liu, P.A. Jose, J. Yang, C. Zeng, Importance of extracellular vesicles in hypertension. Exp. Biol. Med. 246(3), 342–353 (2020)CrossRef
25.
go back to reference J.J. Gildea, J.E. Seaton, K.G. Victor, C.M. Reyes, D. Bigler Wang, A.C. Pettigrew, C.E. Courtner, N. Shah, H.T. Tran, R.E. Van Sciver, J.M. Carlson, R.A. Felder, Exosomal transfer from human renal proximal tubule cells to distal tubule and collecting duct cells. Clin. Biochem 47(15), 89–94 (2014)PubMedPubMedCentralCrossRef J.J. Gildea, J.E. Seaton, K.G. Victor, C.M. Reyes, D. Bigler Wang, A.C. Pettigrew, C.E. Courtner, N. Shah, H.T. Tran, R.E. Van Sciver, J.M. Carlson, R.A. Felder, Exosomal transfer from human renal proximal tubule cells to distal tubule and collecting duct cells. Clin. Biochem 47(15), 89–94 (2014)PubMedPubMedCentralCrossRef
26.
go back to reference E.R. Barros, C.A. Carvajal, Urinary exosomes and their cargo: potential biomarkers for mineralocorticoid arterial hypertension? Front Endocrinol. 8, 230 (2017)CrossRef E.R. Barros, C.A. Carvajal, Urinary exosomes and their cargo: potential biomarkers for mineralocorticoid arterial hypertension? Front Endocrinol. 8, 230 (2017)CrossRef
27.
go back to reference A. Tapia-Castillo, D. Guanzon, C. Palma, A. Lai, E. Barros, F. Allende, A. Vecchiola, C.E. Fardella, C. Salomón, C.A. Carvajal, Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess. J. Transl. Med. 17(1), 1–11. (2019)CrossRef A. Tapia-Castillo, D. Guanzon, C. Palma, A. Lai, E. Barros, F. Allende, A. Vecchiola, C.E. Fardella, C. Salomón, C.A. Carvajal, Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess. J. Transl. Med. 17(1), 1–11. (2019)CrossRef
28.
go back to reference A. Tapia-Castillo, D. Guanzon, C. Palma, A. Lai, E. Barros, F. Allende, A. Vecchiola, C.E. Fardella, C. Salomon, C.A. Carvajal, Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess. J. Transl. Med. 17(1), 392 (2019)PubMedPubMedCentralCrossRef A. Tapia-Castillo, D. Guanzon, C. Palma, A. Lai, E. Barros, F. Allende, A. Vecchiola, C.E. Fardella, C. Salomon, C.A. Carvajal, Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess. J. Transl. Med. 17(1), 392 (2019)PubMedPubMedCentralCrossRef
29.
go back to reference P. Mulatero, F. Rabbia, A. Milan, C. Paglieri, F. Morello, L. Chiandussi, F. Veglio, Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40(6), 897–902 (2002)PubMedCrossRef P. Mulatero, F. Rabbia, A. Milan, C. Paglieri, F. Morello, L. Chiandussi, F. Veglio, Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40(6), 897–902 (2002)PubMedCrossRef
30.
go back to reference J. Montero, J. Soto, C. Fardella, A. Foradori, G. Valdes, Measurement of low levels of plasma renin activity. A methodological improvement. Rev. Med Chil. 126(2), 151–154 (1998)PubMed J. Montero, J. Soto, C. Fardella, A. Foradori, G. Valdes, Measurement of low levels of plasma renin activity. A methodological improvement. Rev. Med Chil. 126(2), 151–154 (1998)PubMed
31.
go back to reference C. Campino, C. Hill, R. Baudrand, A. Martinez-Aguayo, M. Aglony, C.A. Carrasco, C. Ferrada, C. Loureiro, A. Vecchiola, R. Bancalari, F. Grob, C.A. Carvajal, C.F. Lagos, C. Valdivia, A. Tapia-Castillo, C.A. Fuentes, C. Mendoza, H. Garcia, R. Uauy, C.E. Fardella, Usefulness and pitfalls in sodium intake estimation: comparison of dietary assessment and urinary excretion in Chilean children and adults. Am. J. Hypertens. 29(10), 1212–1217 (2016)PubMedCrossRef C. Campino, C. Hill, R. Baudrand, A. Martinez-Aguayo, M. Aglony, C.A. Carrasco, C. Ferrada, C. Loureiro, A. Vecchiola, R. Bancalari, F. Grob, C.A. Carvajal, C.F. Lagos, C. Valdivia, A. Tapia-Castillo, C.A. Fuentes, C. Mendoza, H. Garcia, R. Uauy, C.E. Fardella, Usefulness and pitfalls in sodium intake estimation: comparison of dietary assessment and urinary excretion in Chilean children and adults. Am. J. Hypertens. 29(10), 1212–1217 (2016)PubMedCrossRef
32.
go back to reference A. Tapia-Castillo, R. Baudrand, A. Vaidya, C. Campino, F. Allende, C. Valdivia, A. Vecchiola, C.F. Lagos, C.A. Fuentes, S. Solari, A. Martínez-Aguayo, H. García, C.A. Carvajal, C.E. Fardella, Clinical, biochemical, and genetic characteristics of “nonclassic” apparent mineralocorticoid excess syndrome. J. Clin. Endocrinol. Metab. 104(2), 595–603 (2019)PubMedCrossRef A. Tapia-Castillo, R. Baudrand, A. Vaidya, C. Campino, F. Allende, C. Valdivia, A. Vecchiola, C.F. Lagos, C.A. Fuentes, S. Solari, A. Martínez-Aguayo, H. García, C.A. Carvajal, C.E. Fardella, Clinical, biochemical, and genetic characteristics of “nonclassic” apparent mineralocorticoid excess syndrome. J. Clin. Endocrinol. Metab. 104(2), 595–603 (2019)PubMedCrossRef
33.
go back to reference P.K. Whelton, R.M. Carey, W.S. Aronow, D.E. Casey, K.J. Collins, C.D. Himmelfarb, S.M. DePalma, S. Gidding, K.A. Jamerson, D.W. Jones, E.J. MacLaughlin, P. Muntner, B. Ovbiagele, S.C. Smith, C.C. Spencer, R.S. Stafford, S.J. Taler, R.J. Thomas, K.A. Williams, J.D. Williamson, J.T. Wright, 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71(6), e13–e115 (2018)PubMed P.K. Whelton, R.M. Carey, W.S. Aronow, D.E. Casey, K.J. Collins, C.D. Himmelfarb, S.M. DePalma, S. Gidding, K.A. Jamerson, D.W. Jones, E.J. MacLaughlin, P. Muntner, B. Ovbiagele, S.C. Smith, C.C. Spencer, R.S. Stafford, S.J. Taler, R.J. Thomas, K.A. Williams, J.D. Williamson, J.T. Wright, 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71(6), e13–e115 (2018)PubMed
34.
go back to reference P.K. Whelton, R.M. Carey, W.S. Aronow, D.E. Casey Jr., K.J. Collins, C. Dennison Himmelfarb, S.M. DePalma, S. Gidding, K.A. Jamerson, D.W. Jones, E.J. MacLaughlin, P. Muntner, B. Ovbiagele, S.C. Smith Jr., C.C. Spencer, R.S. Stafford, S.J. Taler, R.J. Thomas, K.A. Williams Sr., J.D. Williamson, J.T. Wright Jr., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 71(19), e127–e248 (2018)PubMedCrossRef P.K. Whelton, R.M. Carey, W.S. Aronow, D.E. Casey Jr., K.J. Collins, C. Dennison Himmelfarb, S.M. DePalma, S. Gidding, K.A. Jamerson, D.W. Jones, E.J. MacLaughlin, P. Muntner, B. Ovbiagele, S.C. Smith Jr., C.C. Spencer, R.S. Stafford, S.J. Taler, R.J. Thomas, K.A. Williams Sr., J.D. Williamson, J.T. Wright Jr., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 71(19), e127–e248 (2018)PubMedCrossRef
35.
go back to reference P.K. Whelton, R.M. Carey, W.S. Aronow, D.E. Casey Jr., K.J. Collins, C. Dennison Himmelfarb, S.M. DePalma, S. Gidding, K.A. Jamerson, D.W. Jones, E.J. MacLaughlin, P. Muntner, B. Ovbiagele, S.C. Smith Jr., C.C. Spencer, R.S. Stafford, S.J. Taler, R.J. Thomas, K.A. Williams Sr., J.D. Williamson, J.T. Wright Jr., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 71(6), 1269–1324 (2017) P.K. Whelton, R.M. Carey, W.S. Aronow, D.E. Casey Jr., K.J. Collins, C. Dennison Himmelfarb, S.M. DePalma, S. Gidding, K.A. Jamerson, D.W. Jones, E.J. MacLaughlin, P. Muntner, B. Ovbiagele, S.C. Smith Jr., C.C. Spencer, R.S. Stafford, S.J. Taler, R.J. Thomas, K.A. Williams Sr., J.D. Williamson, J.T. Wright Jr., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 71(6), 1269–1324 (2017)
36.
go back to reference A. Martinez-Aguayo, C. Campino, R. Baudrand, C.A. Carvajal, H. García, M. Aglony, R. Bancalari, L. García, C. Loureiro, A. Vecchiola, A. Tapia-Castillo, C. Valdivia, S. Sanhueza, C.A. Fuentes, C.F. Lagos, S. Solari, F. Allende, A.M. Kalergis, C.E. Fardella, Cortisol/cortisone ratio and matrix metalloproteinase-9 activity are associated with pediatric primary hypertension. J. Hypertens. 34(9), 1808–1814 (2016)PubMedCrossRef A. Martinez-Aguayo, C. Campino, R. Baudrand, C.A. Carvajal, H. García, M. Aglony, R. Bancalari, L. García, C. Loureiro, A. Vecchiola, A. Tapia-Castillo, C. Valdivia, S. Sanhueza, C.A. Fuentes, C.F. Lagos, S. Solari, F. Allende, A.M. Kalergis, C.E. Fardella, Cortisol/cortisone ratio and matrix metalloproteinase-9 activity are associated with pediatric primary hypertension. J. Hypertens. 34(9), 1808–1814 (2016)PubMedCrossRef
37.
go back to reference C.R. Wade, A.M. van Rij, Plasma thiobarbituric acid reactivity: reaction conditions and the role of iron, antioxidants and lipid peroxy radicals on the quantitation of plasma lipid peroxides. Life Sci. 43(13), 1085–1093 (1988)PubMedCrossRef C.R. Wade, A.M. van Rij, Plasma thiobarbituric acid reactivity: reaction conditions and the role of iron, antioxidants and lipid peroxy radicals on the quantitation of plasma lipid peroxides. Life Sci. 43(13), 1085–1093 (1988)PubMedCrossRef
38.
go back to reference C. Campino, A. Martinez-Aguayo, R. Baudrand, C.A. Carvajal, M. Aglony, H. Garcia, O. Padilla, A.M. Kalergis, C.E. Fardella, Age-related changes in 11beta-hydroxysteroid dehydrogenase type 2 activity in normotensive subjects. Am. J. Hypertens. 26(4), 481–487 (2013)PubMedCrossRef C. Campino, A. Martinez-Aguayo, R. Baudrand, C.A. Carvajal, M. Aglony, H. Garcia, O. Padilla, A.M. Kalergis, C.E. Fardella, Age-related changes in 11beta-hydroxysteroid dehydrogenase type 2 activity in normotensive subjects. Am. J. Hypertens. 26(4), 481–487 (2013)PubMedCrossRef
39.
go back to reference S. Sarker, K. Scholz-Romero, A. Perez, S.E. Illanes, M.D. Mitchell, G.E. Rice, C. Salomon, Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. J. Transl. Med. 12, 204 (2014)PubMedPubMedCentralCrossRef S. Sarker, K. Scholz-Romero, A. Perez, S.E. Illanes, M.D. Mitchell, G.E. Rice, C. Salomon, Placenta-derived exosomes continuously increase in maternal circulation over the first trimester of pregnancy. J. Transl. Med. 12, 204 (2014)PubMedPubMedCentralCrossRef
40.
go back to reference E. Feraille, D. Mordasini, S. Gonin, G. Deschenes, M. Vinciguerra, A. Doucet, A. Vandewalle, V. Summa, F. Verrey, P.Y. Martin, Mechanism of control of Na,K-ATPase in principal cells of the mammalian collecting duct. Ann. N.Y. Acad. Sci. 986, 570–578 (2003)PubMedCrossRef E. Feraille, D. Mordasini, S. Gonin, G. Deschenes, M. Vinciguerra, A. Doucet, A. Vandewalle, V. Summa, F. Verrey, P.Y. Martin, Mechanism of control of Na,K-ATPase in principal cells of the mammalian collecting duct. Ann. N.Y. Acad. Sci. 986, 570–578 (2003)PubMedCrossRef
41.
go back to reference R. Baudrand, A. Vaidya, The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor. Int J Mol Sci. 19(2), 546 (2018) R. Baudrand, A. Vaidya, The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor. Int J Mol Sci. 19(2), 546 (2018)
42.
go back to reference P. Kolkhof, M. Delbeck, A. Kretschmer, W. Steinke, E. Hartmann, L. Barfacker, F. Eitner, B. Albrecht-Kupper, S. Schafer, Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovascular Pharmacol. 64(1), 69–78 (2014)CrossRef P. Kolkhof, M. Delbeck, A. Kretschmer, W. Steinke, E. Hartmann, L. Barfacker, F. Eitner, B. Albrecht-Kupper, S. Schafer, Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovascular Pharmacol. 64(1), 69–78 (2014)CrossRef
43.
go back to reference J. Chong, J. Fotheringham, C. Tomson, T. Ellam, Renal albumin excretion in healthy young adults and its association with mortality risk in the US population. Nephrol. Dial. Transplant. 35(3), 458–464 (2020)PubMedCrossRef J. Chong, J. Fotheringham, C. Tomson, T. Ellam, Renal albumin excretion in healthy young adults and its association with mortality risk in the US population. Nephrol. Dial. Transplant. 35(3), 458–464 (2020)PubMedCrossRef
44.
go back to reference D.F. Marquez, G. Ruiz-Hurtado, J. Segura, L. Ruilope, Microalbuminuria and cardiorenal risk: old and new evidence in different populations. F1000Res. 8(F1000 Faculty Rev), 1659 (2019) D.F. Marquez, G. Ruiz-Hurtado, J. Segura, L. Ruilope, Microalbuminuria and cardiorenal risk: old and new evidence in different populations. F1000Res. 8(F1000 Faculty Rev), 1659 (2019)
45.
go back to reference S. Gorini, V. Marzolla, C. Mammi, A. Armani, M. Caprio, Mineralocorticoid receptor and aldosterone-related biomarkers of end-organ damage in cardiometabolic disease. Biomolecules. 8(3), 96 (2018) S. Gorini, V. Marzolla, C. Mammi, A. Armani, M. Caprio, Mineralocorticoid receptor and aldosterone-related biomarkers of end-organ damage in cardiometabolic disease. Biomolecules. 8(3), 96 (2018)
46.
go back to reference A. Tarjus, E. Martinez-Martinez, C. Amador, C. Latouche, S. El Moghrabi, T. Berger, T.W. Mak, R. Fay, N. Farman, P. Rossignol, F. Zannad, N. Lopez-Andres, F. Jaisser, Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids. Hypertension 66(1), 158–166 (2015)PubMedCrossRef A. Tarjus, E. Martinez-Martinez, C. Amador, C. Latouche, S. El Moghrabi, T. Berger, T.W. Mak, R. Fay, N. Farman, P. Rossignol, F. Zannad, N. Lopez-Andres, F. Jaisser, Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids. Hypertension 66(1), 158–166 (2015)PubMedCrossRef
48.
go back to reference M.L. Martinez, L.F. Lopes, E.B. Coelho, F. Nobre, J.B. Rocha, R.F. Gerlach, J.E. Tanus-Santos, Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J. cardiovascular Pharmacol. 47(1), 117–122 (2006)CrossRef M.L. Martinez, L.F. Lopes, E.B. Coelho, F. Nobre, J.B. Rocha, R.F. Gerlach, J.E. Tanus-Santos, Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J. cardiovascular Pharmacol. 47(1), 117–122 (2006)CrossRef
49.
go back to reference M. Flamant, S. Placier, C. Dubroca, B. Esposito, I. Lopes, C. Chatziantoniou, A. Tedgui, J.C. Dussaule, S. Lehoux, Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 50(1), 212–218 (2007)PubMedCrossRef M. Flamant, S. Placier, C. Dubroca, B. Esposito, I. Lopes, C. Chatziantoniou, A. Tedgui, J.C. Dussaule, S. Lehoux, Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 50(1), 212–218 (2007)PubMedCrossRef
50.
go back to reference J. Zhang, Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev. Cardiovasc Med. 23(2), 73 (2022)PubMedCrossRef J. Zhang, Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev. Cardiovasc Med. 23(2), 73 (2022)PubMedCrossRef
51.
go back to reference C.A. Carvajal, A. Tapia-Castillo, J.A. Pérez, C.E. Fardella, Serum Alpha-1-Acid Glycoprotein-1 and urinary extracellular vesicle miR-21-5p as potential biomarkers of primary aldosteronism. Front Immunol. 12, 768734 (2021)PubMedPubMedCentralCrossRef C.A. Carvajal, A. Tapia-Castillo, J.A. Pérez, C.E. Fardella, Serum Alpha-1-Acid Glycoprotein-1 and urinary extracellular vesicle miR-21-5p as potential biomarkers of primary aldosteronism. Front Immunol. 12, 768734 (2021)PubMedPubMedCentralCrossRef
52.
go back to reference D.G. Romero, M.W. Plonczynski, C.A. Carvajal, E.P. Gomez-Sanchez, C.E. Gomez-Sanchez, Microribonucleic acid-21 increases aldosterone secretion and proliferation in H295R human adrenocortical cells. Endocrinology 149(5), 2477–2483 (2008)PubMedPubMedCentralCrossRef D.G. Romero, M.W. Plonczynski, C.A. Carvajal, E.P. Gomez-Sanchez, C.E. Gomez-Sanchez, Microribonucleic acid-21 increases aldosterone secretion and proliferation in H295R human adrenocortical cells. Endocrinology 149(5), 2477–2483 (2008)PubMedPubMedCentralCrossRef
53.
go back to reference M.A. Baker, F. Wang, Y. Liu, A.J. Kriegel, A.M. Geurts, K. Usa, H. Xue, D. Wang, Y. Kong, M. Liang, MiR-192-5p in the kidney protects against the development of hypertension. Hypertension 73(2), 399–406 (2019)PubMedCrossRef M.A. Baker, F. Wang, Y. Liu, A.J. Kriegel, A.M. Geurts, K. Usa, H. Xue, D. Wang, Y. Kong, M. Liang, MiR-192-5p in the kidney protects against the development of hypertension. Hypertension 73(2), 399–406 (2019)PubMedCrossRef
54.
go back to reference S.M. Koval, I.O. Snihurska, K.O. Yushko, O.V. Mysnychenko, M.Y. Penkova, O.M. Lytvynova, A.E. Berezin, V.S. Lytvynov, Circulating microRNA-133a in patients with arterial hypertension, hypertensive heart disease, and left ventricular diastolic dysfunction. Front Cardiovasc Med 7, 104 (2020)PubMedPubMedCentralCrossRef S.M. Koval, I.O. Snihurska, K.O. Yushko, O.V. Mysnychenko, M.Y. Penkova, O.M. Lytvynova, A.E. Berezin, V.S. Lytvynov, Circulating microRNA-133a in patients with arterial hypertension, hypertensive heart disease, and left ventricular diastolic dysfunction. Front Cardiovasc Med 7, 104 (2020)PubMedPubMedCentralCrossRef
55.
go back to reference M. Abdellatif, The role of microRNA-133 in cardiac hypertrophy uncovered. Circulation Res. 106(1), 16–18 (2010)PubMedCrossRef M. Abdellatif, The role of microRNA-133 in cardiac hypertrophy uncovered. Circulation Res. 106(1), 16–18 (2010)PubMedCrossRef
56.
go back to reference S.J. Matkovich, W. Wang, Y. Tu, W.H. Eschenbacher, L.E. Dorn, G. Condorelli, A. Diwan, J.M. Nerbonne, G.W. Dorn 2nd, MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circulation Res. 106(1), 166–175 (2010)PubMedCrossRef S.J. Matkovich, W. Wang, Y. Tu, W.H. Eschenbacher, L.E. Dorn, G. Condorelli, A. Diwan, J.M. Nerbonne, G.W. Dorn 2nd, MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circulation Res. 106(1), 166–175 (2010)PubMedCrossRef
57.
go back to reference G. Castoldi, C.R. Di Gioia, C. Bombardi, D. Catalucci, B. Corradi, M.G. Gualazzi, M. Leopizzi, M. Mancini, G. Zerbini, G. Condorelli, A. Stella, MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J. Cell. Physiol. 227(2), 850–856 (2012)PubMedCrossRef G. Castoldi, C.R. Di Gioia, C. Bombardi, D. Catalucci, B. Corradi, M.G. Gualazzi, M. Leopizzi, M. Mancini, G. Zerbini, G. Condorelli, A. Stella, MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J. Cell. Physiol. 227(2), 850–856 (2012)PubMedCrossRef
58.
go back to reference A. Angelini, Z. Li, M. Mericskay, J.F. Decaux, Regulation of connective tissue growth factor and cardiac fibrosis by an SRF/MicroRNA-133a axis. PLoS ONE 10(10), e0139858 (2015)PubMedPubMedCentralCrossRef A. Angelini, Z. Li, M. Mericskay, J.F. Decaux, Regulation of connective tissue growth factor and cardiac fibrosis by an SRF/MicroRNA-133a axis. PLoS ONE 10(10), e0139858 (2015)PubMedPubMedCentralCrossRef
59.
go back to reference J.P. Ball, M. Syed, R.O. Maranon, M.E. Hall, R. Kc, J.F. Reckelhoff, L.L. Yanes Cardozo, D.G. Romero, Role and regulation of MicroRNAs in aldosterone-mediated cardiac injury and dysfunction in male rats. Endocrinology 158(6), 1859–1874 (2017)PubMedPubMedCentralCrossRef J.P. Ball, M. Syed, R.O. Maranon, M.E. Hall, R. Kc, J.F. Reckelhoff, L.L. Yanes Cardozo, D.G. Romero, Role and regulation of MicroRNAs in aldosterone-mediated cardiac injury and dysfunction in male rats. Endocrinology 158(6), 1859–1874 (2017)PubMedPubMedCentralCrossRef
60.
go back to reference M. Syed, J.P. Ball, K.W. Mathis, M.E. Hall, M.J. Ryan, M.E. Rothenberg, L.L. Yanes Cardozo, D.G. Romero, MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction. Am. J. Physiol. Endocrinol. Metab. 315(6), E1154–E1167 (2018)PubMedPubMedCentralCrossRef M. Syed, J.P. Ball, K.W. Mathis, M.E. Hall, M.J. Ryan, M.E. Rothenberg, L.L. Yanes Cardozo, D.G. Romero, MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction. Am. J. Physiol. Endocrinol. Metab. 315(6), E1154–E1167 (2018)PubMedPubMedCentralCrossRef
Metadata
Title
Clinical, biochemical, and miRNA profile of subjects with positive screening of primary aldosteronism and nonclassic apparent mineralocorticoid excess
Authors
Alejandra Tapia-Castillo
Cristian A. Carvajal
Jorge A. Pérez
Carlos E. Fardella
Publication date
08-06-2022
Publisher
Springer US
Published in
Endocrine / Issue 2/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-03103-x

Other articles of this Issue 2/2022

Endocrine 2/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.